The financial information provided outlines the financial statements of The Cigna Group for the three months ending in March 2023, including details on revenues, expenses, net income, comprehensive income, balance sheets, and changes in total equity. Key financial figures such as revenues, premiums, fees, net income, and shareholders' equity are provided, as well as a breakdown of assets, liabilities, and cash flows from operating, investing, and financing activities. The Cigna Group operates as a global health company offering a variety of health-related products and services, primarily targeting employers, government organizations, and individuals in the U.S. and selected international markets. The company operates through segments such as Evernorth Health Services and Cigna Healthcare, providing pharmacy, medical, dental, behavioral, and related products and services to its clients and customers. The text also discusses financial data related to future policy benefits, other operations, contractholder deposit funds, and market risk benefits of an insurance company, including details about liabilities, assets, interest rates, duration, obligations, recoverables, accounting policies, customer deposits, reinsurance agreements, investment portfolios, and credit rating considerations. Additionally, it outlines specific balances, changes, and policies related to various aspects of the company's operations.
The text provides a detailed overview of the Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A) for a company as of March 31, 2023. It covers various segments, financial highlights, investment assets, market risks, and critical accounting estimates. The Executive Overview touches on liquidity, capital resources, and provides a cautionary note regarding forward-looking statements. The different segments, including Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate, are discussed in detail, outlining financial results and key factors impacting performance. The segments had revenue adjustments totaling $46.5 billion, with notable changes in adjusted revenues and gross profit percentages. The text also delves into investment assets, market risks, and critical accounting estimates, offering insights into the analysis of financial standing and operational results.
The text provided indicates that the information related to market risk, both quantitative and qualitative disclosures, can be found in the section titled "Market Risk" in Item 2 above, specifically in the Management's Discussion and Analysis of Financial Condition and Results of Operations, which is incorporated into the current section by reference.
The text discusses the evaluation of The Cigna Group's disclosure controls and procedures and the conclusion by the Chief Executive Officer and Chief Financial Officer that these controls are effective in ensuring proper disclosure of information. Additionally, it mentions that there have been no material changes in the internal control over financial reporting of The Cigna Group during the period covered by the report.
The text provided refers to legal proceedings and states that the information contained under "Legal and Regulatory Matters" in Note 16 to the Consolidated Financial Statements is included by reference.
The text provides information on where to find details about factors that could impact the company's financial performance by referring to the "Risk Factors" section in the Annual Report on Form 10-K for the year ended December 31, 2022.
The text discusses The Cigna Group's share repurchase activity for the quarter ended March 31, 2023. They repurchased a total of 3,552,220 shares at an average price of $298.82 per share. The company's publicly announced program allowed for further repurchase, with $3,199,178 worth of shares still available for purchase. Employees also tendered shares under the company's equity compensation plans. Additionally, the company repurchased 0.5 million shares for approximately $139 million between April 1, 2023, and May 4, 2023, leaving repurchase authority at $2.5 billion as of May 4, 2023.
I apologize, but I cannot see any text parts that you have sent. Can you please share the text you would like me to summarize?
I apologize for the confusion, but I cannot summarize text without the actual content to work with. Could you please provide the text you would like me to summarize?
The text refers to incorporating information regarding the "Supplemental Pharmacy Benefit Management Model Disclosure" from Exhibit 20.1 to Form 10-Q into the current document.
The provided text outlines various exhibits included in a financial report filed by The Cigna Group. These include the restated certificate of incorporation, amended by-laws, supplemental indenture, offer letters, certification of executives, and financial statements formatted in Inline XBRL. The report is signed by Brian C. Evanko, the Executive Vice President and Chief Financial Officer of The Cigna Group, on May 5, 2023.
